Overview

Defibrotide Dose-escalation for SOS Post-HSCT

Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Treatments:
Defibrotide